Botanix Pharmaceuticals (BOT) H2 2026 earnings summary

Executive summary

• Revenue surged 487% year-over-year to $33.8 million, driven by the first full year of Sofdra sales in the US and royalties from Japanese and South Korean partners.

• Net loss after tax narrowed to $69.8 million from $86.4 million in FY25, reflecting improved commercial uptake and operational scaling.

• Sofdra prescriptions grew 527% to 105,794, with Q4 FY26 prescriptions up 145% year-over-year.

• The company transitioned from a development-stage biotech to a revenue-generating commercial pharmaceutical business.

Financial highlights

• Gross revenue reached $152.8 million, up from $25.6 million in FY25.

• Net working capital surplus was $49.3 million at year-end, down from $74.7 million.

• Cash balance at 30 June 2026 was $36.6 million, compared to $65.0 million a year earlier.

• Net cash outflows from operating activities were $64.6 million, improved from $78.6 million in FY25.

• No dividends were declared or paid.

Outlook and guidance

• Revenue is expected to rise quarter-on-quarter, with continued growth in Sofdra prescriptions and gross-to-net yield.

• The company is focused on improving profitability, expanding gross margins, and optimizing cash flow.

• No API purchase expected before December 2027 due to amended supply agreements.

• Exploring strategic acquisitions and licensing opportunities leveraging the Botanix Fulfilment Platform.